Up a level |
Bland, Philip, Saville, Harry, Wai, Patty T, Curnow, Lucinda, Muirhead, Gareth, Nieminuszczy, Jadwiga, Ravindran, Nivedita, John, Marie Beatrix, Hedayat, Somaieh, Barker, Holly E et al (show 29 more authors)
(2023)
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
NATURE GENETICS, 55 (8).
1311-+.
Kennedy, Emma, Coulter, Eve Marie, Halliwell, Emma, Profitos-Peleja, Nuria, Walsby, Elisabeth, Clark, Barnaby, Phillips, Elizabeth H, Burley, Thomas A, Mitchell, Simon, Devereux, Stephen et al (show 13 more authors)
(2021)
TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.
Blood, 137 (22).
pp. 3064-3078.
Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew et al (show 9 more authors)
(2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY, 182 (3).
pp. 429-433.